The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Results for trial of LCL161 for PMF, post-PV MF, and post-ET MF patients
Naveen Pemmaraju, MD of the MD Anderson Cancer Center, Houston, TX explains an ongoing Phase II clinical trial of LCL16 in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocytosis myelofibrosis (post-ET MF) (NCT02098161). LCL161 is a SMAC mimetic and antagonist of the inhibitor of apoptosis protein, and used for the first time for patients with these rare disorders in this study. Initial results have been encouraging, and the plan is to continue enrolling. Dr Naveen points to the possibility of immune system side effects. Recorded at Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
